References: STI Update – What’s New in Diagnosis, Treatment & Prevention

References for CME Article

"What’s New in Adult Sexually Transmitted Infections Management and Prevention for 2024"

References

• [1] Sexually Transmitted Infections (STIs). CDC. Last Reviewed: January 30, 2024 Retrieved from: https://www.cdc.gov/std/statistics/2022/default.htm

• [2] National Overview of STIs in 2023. CDC. November 12, 2024. Retrieved from: https://www.cdc.gov/sti-statistics/annual/summary.html

• [3] Multi-drug resistant gonorrhoea. WHO. July 4, 2024. Retrieved from: https://www.who.int/news-room/fact-sheets/detail/multi-drug-resistant-gonorrhoea

• [4] Zhu X et al. Ceftriaxone-Resistant Gonorrhea — China, 2022. CDC Morbidity and Mortality Weekly Report. March 28, 2024 / 73(12);255–259, Retrieved from: https://www.cdc.gov/mmwr/volumes/73/wr/mm7312a2.htm?s_cid=mm7312a2_w

• [5] Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020. CDC-Morbidity and Mortality Weekly Report. December 18, 2020 / 69(50);1911–1916. Retrieved from: https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm

• [6] Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea. Businesswire.  November 01, 2023. Retrieved from: https://www.businesswire.com/news/home/20231101634842/en/Positive-Results-Announced-in-Largest-Pivotal-Phase-3-Trial-of-a-First-in-Class-Oral-Antibiotic-to-Treat-Uncomplicated-Gonorrhea

• [7] NIH Statement on Preliminary Efficacy Results of First-in-Class Gonorrhea Antibiotic Developed Through Public-Private Partnership. NIH. November 1, 2023. Retrieved from: https://www.niaid.nih.gov/news-events/nih-statement-preliminary-efficacy-results-first-class-gonorrhea-antibiotic-developed

• [8] Exploring a Meningitis Vaccine for Gonorrhea Prevention. NIH. May 10, 2024. https://www.niaid.nih.gov/news-events/meningitis-vaccine-gonorrhea-prevention

• [9] Johnson B. GSK’s gonorrhea vaccine receives fast-track designation to expedite clinical trials. Nature. 07 August 2023. Retrieved from: https://www.nature.com/articles/d41591-023-00069-9

• [10] Roier S et al. A novel mechanism for the biogenesis of outer membrane vesicles in Gram-negative bacteria. Nat Commun. 2016;7:10515. Published 2016 Jan 25. Retrieved from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4737802/

• [11] Gonococcal Infections Among Adolescents and Adults. CDC. Last Reviewed: September 21, 2022. Retrieved from: https://www.cdc.gov/std/treatment-guidelines/gonorrhea-adults.htm

• [12] Syphilis. WHO. 21 May 2024. Retrieved from: https://www.who.int/news-room/fact-sheets/detail/syphilis

• [13] Kojima N, Konda KA, Klausner JD. Notes on syphilis vaccine development. Front Immunol. 2022;13:952284. Published 2022 Jul 28. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365935/

• [14] Primary and Secondary Syphilis. CDC Sexually Transmitted Infections Treatment Guidelines, 2021. Last Reviewed: July 22, 2021. Retrieved from: https://www.cdc.gov/std/treatment-guidelines/p-and-s-syphilis.htm

• [15] Syphilis During Pregnancy. CDC Sexually Transmitted Infections Treatment Guidelines, 2021. Last Reviewed: July 22, 2021. Retrieved from: https://www.cdc.gov/std/treatment-guidelines/syphilis-pregnancy.htm

• [16] Syphilis. CDC. Last Reviewed: October 3, 2024. Retrieved from: https://www.cdc.gov/std/treatment-guidelines/syphilis.htm

• [17] Bachmann LH, Mena L. Clinical Reminders during Bicillin L-A® Shortage. CDC. February 26, 2024, updated  September 9, 2024‎. Retrieved from: https://www.cdc.gov/sti/php/from-the-director/2023-07-20-mena-bicillin.html

• [18] Sexually transmitted infections (STIs). WHO. 21 May 2024. https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)

• [19] Chlamydial Infections. CDC. Last Reviewed: July 22, 2021. Retrieved from: https://www.cdc.gov/std/treatment-guidelines/chlamydia.htm

• [20] Legal Status of Expedited Partner Therapy (EPT). July 16, 2024. Retrieved from: https://www.cdc.gov/sti/php/ept-legal-status/?CDC_AAref_Val=https://www.cdc.gov/std/ept/legal/default.htm

• [21] Abraham S et al. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Infectious Diseases, Volume 19, Issue 10, 1091 - 1100. October 2019. Retrieved from: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30279-8/abstract

• [22] Trichomoniasis. CDC. Last Reviewed: September 21, 2022. Retrieved from: https://www.cdc.gov/std/treatment-guidelines/trichomoniasis.htm

• [23] Trichomoniasis. WHO. 16 October 2023. Retrieved from: https://www.who.int/news-room/fact-sheets/detail/trichomoniasis

• [24] Nezhad G et al. Introduction of protein vaccine candidate based on AP65, AP33, and α-actinin proteins against Trichomonas vaginalis parasite: an immunoinformatics design. Parasites Vectors 17, 165 (2024). Retrieved from: https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-024-06248-y

• [25] Johnson V. CRISPR-Editing EBT-101 Therapy Safe, Temporarily Suppresses HIV Infection. CGT Live. May 21, 2024. Retrieved from:  https://www.cgtlive.com/view/crispr-editing-ebt-101-therapy-safe-temporarily-suppresses-hiv-infection

• [26] Cox D, Barros Guinle MI.  This preventive drug could be a 'game changer' in ending the HIV epidemic. NPR, Goats and Soda - Stories of Life In a Changing World.  September 17, 2024. Retrieved from: https://www.npr.org/sections/goats-and-soda/2024/09/17/g-s1-23248/hiv-drug-aids-epidemic-lenacapavir

• [27] Bekker LG et al. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. NEJM. July 24, 2024. https://www.nejm.org/doi/full/10.1056/NEJMoa2407001

• [28] Herpes simplex virus. WHO. 13 September 2024. Retrieved from: https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus

• [29] About Genital Herpes. CDC. February 20, 2024. Retrieved from: https://www.cdc.gov/herpes/about/index.html

• [30] Nadia A et al. CRISPR-Cas9-mediated genome editing delivered by a single AAV9 vector inhibits HSV-1 reactivation in a latent rabbit keratitis model. Molecular Therapy Methods & Clinical Development, Volume 32, Issue 3. Retrieved from:  https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(24)00119-0

• [31] Human papillomavirus and cancer, WHO. 5 March 2024. Retrieved from: https://www.who.int/news-room/fact-sheets/detail/human-papilloma-virus-and-cancer

• [32] Clinical Overview of HPV. CDC. July 9, 2024. Retrieved from: https://www.cdc.gov/hpv/hcp/clinical-overview/index.html

• [33] About HPV. CDC. July 3, 2024. Retrieved from: https://www.cdc.gov/hpv/about/index.html

• [34] HPV Vaccine Recommendations. CDC, July 9, 2024, Retrieved from: https://www.cdc.gov/hpv/hcp/vaccination-considerations/index.html

• [35] Mycoplasma genitalium. CDC. Last Reviewed: July 22, 2021. Retrieved from: https://www.cdc.gov/std/treatment-guidelines/mycoplasmagenitalium.htm

• [36] Treatment of Mycoplasma genitalium infection in pregnancy: A systematic review of international guidelines. International Journal of Obstetrics & Gynecology. Volume166, Issue1, Pages 27-34. July 2024.  Retrieved from: https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1002/ijgo.15469

• [37]Mycoplasma genitalium. Australian STI Management

• Guidelines for Use in Primary Care. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). Last updated: April, 2024. Retrieved from: https://sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium/